Sirnaomics

Sirnaomics is a biopharmaceutical company developing clinical-stage bio-pharmaceuticals and therapeutics for life-threatening diseases. The company was founded by Patrick Y. Lu in 2007, in Washington DC, Virginia, United States.

The focus of Sirnaomics is to create RNA therapeutics to treat critical diseases such as cancer or fibrosis diseases. Developing novel siRNA-based therapeutics through their proprietary algorithm for sequencing predictions allows them to treat against specific gene targets and identify siRNAs for use against non-drugable targets.

Treatments that Sirnaomics has created and that are within its pipeline include therapeutics for oncology, anti-fibrosis, anti-viral, and galahead diseases. For oncology, treating non-melanoma skin cancer, liver cancer, bladder cancer, liver cancer, colon cancer, breast cancer, and multiple cancers is their primary focus. Hypertrophic scar reduction, keloid scarless healing, liver fibrosis (both PSC and NASH), and lung fibrosis all have anti-fibrosis solutions or treatments under development. The company is developing treatments for viral diseases such as influenza and the coronavirus. For galahead diseases, Sirnaomics aims to find treatments for anticoagulant therapy, dyslipidemia, metabolic disease, and liver fibrosis.